Meditope Biosciences, Inc. logo

Meditope Biosciences, Inc.

Meditope Biosciences is a biotechnology company developing best-in-class antibody-based cancer therapeutics. Meditope is among several next-generation ADC companies seeking to create homogeneous products by engineering the mAbs to have a fixed number of attachment sites for the cytotoxic agents.

Meditopes technology was initially discovered and developed by Beckman Research Institute at the City of Hope, a National Cancer Institute designated Comprehensive Cancer Center. Here a unique site was discovered within the Fab arm of cetuximab that acts as a very specific keyhole in which a specific small peptide - known as a meditope - is able to bind non-covalently.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.meditope.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
177 E. Colorado Blvd., 2nd Floor,CA 091105,
Pasadena
United States
Email
Contact Number

SnAP technology can be readily used on existing antibodies or incorporated into new antibody development efforts. It offers a simple solution for otherwise expensive and complex production and addresses purification challenges associated with antibody-based products.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/meditope-biosciences-inc-
” connections=”true” suffix=””]

Meditope SnAP – Site-specific, novel Antibody Platform-technology is capable of turning any mAb into a proprietary, sitespecific _Lego-likeÓ system that is able to attach and detach drugs to antibodies without the need for chemical conjugation.

In July 2014, Meditope raised $3.6 Mn in Series A funding from angel investors to advance its proprietary monoclonal antibody (mAb) linker technology platform.